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Original article
Effect of neoadjuvant chemoradiation on preoperative
pulmonary physiology, postoperative respiratory complications
and quality of life in patients with oesophageal cancer
J. A. Elliott1 , L. O’Byrne1, G. Foley2, C. F. Murphy1, S. L. Doyle1,3, S. King1, E. M. Guinan2,
N. Ravi1 and J. V. Reynolds1
1Department of Surgery, Trinity Centre for Health Sciences, Trinity College Dublin, and St James’s Hospital, 2School of Medicine, Trinity College
Dublin, and 3School of Biological Sciences, Dublin Institute of Technology, Dublin, Ireland
Correspondence to: Dr J. A. Elliott, Department of Surgery, Trinity Centre and Institute of Molecular Medicine, St James’s Hospital, Dublin 8, Ireland
(e-mail: jelliott@tcd.ie; @JElliottIRL, @emguinank, @SuzanneLDoyle, @CMASHL1F3, @Surgery_TCD, @stjamesdublin)
Background: It remains controversial whether neoadjuvant chemoradiation (nCRT) for oesophageal
cancer influences operative morbidity, in particular pulmonary, and quality of life. This study combined
clinical outcome data with systematic evaluation of pulmonary physiology to determine the impact of
nCRT on pulmonary physiology and clinical outcomes in locally advanced oesophageal cancer.
Methods: Consecutive patients treated between 2010 and 2016 were included. Three-dimensional
conformal radiation was standard, with a lung dose–volume histogram of V20 less than 25 per cent, and
total radiation between 40 and 41⋅4 Gy. Forced expiratory volume in 1 s (FEV1), forced vital capacity
(FVC) and diffusion capacity for carbon monoxide (DLCO) were assessed at baseline and 1 month after
nCRT. Radiation-induced lung injury (grade 2 or greater), comprehensive complications index (CCI)
and pulmonary complications were monitored prospectively. Health-related quality of life was assessed
among disease-free patients in survivorship.
Results: Some 228 patients were studied. Comparing pulmonary physiology values before with those
after nCRT, FEV1 decreased from mean(s.d.) 96⋅8(17⋅7) to 91⋅5(20⋅4) per cent (–3⋅6(10⋅6) per cent;
P < 0⋅001), FVC from 104⋅9(15⋅6) to 98⋅1(19⋅8) per cent (–3⋅2(11⋅9) per cent; P =0⋅005) and DLCO
from 97⋅6(20⋅7) to 82⋅2(20⋅4) per cent (–14⋅8(14⋅0) per cent; P <0⋅001). Five patients (2⋅2 per cent)
developed radiation-induced lung injury precluding surgical resection. Smoking (P = 0⋅005) and increased
age (P <0⋅001) independently predicted percentage change in DLCO. Carboplatin and paclitaxel with
41⋅4 Gy resulted in a greater DLCO decline than cisplatin and 5-fluorouracil with 40 Gy (P =0⋅001). On
multivariable analysis, post-treatment DLCO predicted CCI (P = 0⋅006), respiratory failure (P =0⋅020)
and reduced physical function in survivorship (P =0⋅047).
Conclusion: These data indicate that modern nCRT alters pulmonary physiology, in particular diffusion
capacity, which is linked to short- and longer-term clinical consequences, highlighting a potentially
modifiable index of risk.
Presented to the Annual Meeting of the European Surgical Association, Trieste, Italy, May 2018
Paper accepted 26 March 2019
Published online 8 July 2019 in Wiley Online Library (www.bjs.co.uk). DOI: 10.1002/bjs.11218
Introduction
Although recent trends indicate reduced postoperative
mortality after oesophagectomy, major morbidity, in par-
ticular pulmonary, remains high, with considerable health
and economic costs1. In a recent modern international
collaborative series1 of 2704 patients from high-volume
centres, with an approximately equal mix of open and
minimally invasive approaches, major respiratory compli-
cations were evident in 28 per cent of patients, pneumonia
in 15 per cent and respiratory failure in 7 per cent. In other
series1,2, respiratory failure was reported in up to 15 per
cent of patients, and was the most common cause of death.
The prediction of risk and prevention of respiratory mor-
bidity are therefore of considerable importance, and in this
© 2019 BJS Society Ltd BJS 2019; 106: 1341–1351
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All patients with locally advanced oesophageal cancer






 Inoperable disease progression n= 18
 Open and close surgery n= 5
 Impaired performance status n= 16
 Radiation-induced lung injury n= 5





HR-QoL, health-related quality of life.
context baseline determination of lung physiology comple-
ments clinical assessment.
Neoadjuvant therapy is increasingly the standard of
care for locally advanced oesophageal cancer, with the
combination of chemotherapy and radiation therapy
underpinned in the modern era by the CROSS trial
(Chemoradiotherapy for Oesophageal Cancer Followed
by Surgery Study)3, which combined 41⋅4 Gy, carboplatin
and paclitaxel. The impact of radiation on lung physiology
and its relevance to postoperative complications and sur-
vivorship are rarely studied. Modern radiation therapy is
underpinned by three-dimensional (3D) conformal meth-
ods or intensity-modulated approaches, and dose–volume
histograms (DVHs) are set to limit radiation delivery to
non-target tissues such as lung; however, approximately
25 per cent of total lung tissue is irradiated up to 20 Gy in
standard protocols. It remains unclear whether this has any
clinical impact, in particular in relation to postoperative
pulmonary complications. On the one hand, in the CROSS
trial3, where 46 per cent of patients experienced pulmonary
complications in the multimodal cohort, there was no dif-
ference compared with surgery alone, with a 4 per cent
operative mortality rate in both cohorts. Moreover, a
meta-analysis4 of RCTs including 431 patients showed no
added risk of respiratory complications or operative mor-
tality with a variety of multimodal protocols. Conversely,
several studies have suggested caution in this interpreta-
tion, as chemoradiation was associated with a significant
fourfold increased operative mortality rate in the FFCD
(Fédération Francophone de Cancérologie Digestive) 9901
RCT5, a threefold but non-significant increase in mortality
compared with chemotherapy in the POET (PreOperative
therapy in Esophagogastric adenocarcinoma) trial6, and
a non-significant doubling of mortality in the NeoRes
(Neoadjuvant Chemotherapy Versus Radiochemotherapy
for Cancer of the Esophagus or Cardia) trial7, with a
significant increase in major pulmonary complications.
It is also inarguable that, until recently, the definition,
prospective documentation and reporting of operative
morbidity, including pneumonia and pulmonary com-
plications, in published RCTs were relatively weak and
inconsistent8. Accordingly, the question of whether neoad-
juvant chemoradiation (nCRT) has a clinical or a more
nuanced impact on pulmonary function remains of great
relevance, and demands rigorous assessment. In this
study, lung function was measured systematically before
and after nCRT, and the incidence of clinically evident
radiation-induced lung injury, subclinical changes in phys-
iology that may be linked to postoperative complications,
and quality of life in survivorship were evaluated.
Methods
The Oesophageal and Gastric Centre at St James’s Hospi-
tal, Dublin, is a high-volume national centre, and a detailed
clinicopathological database is maintained prospectively
for all patients with oesophageal cancer. Records for
consecutive patients with locally advanced oesophageal
cancer treated with nCRT with curative intent over 7 years
between 2010 and 2016 were assessed retrospectively for
inclusion. Patients undergoing emergency or palliative
surgery, or salvage oesophagectomy, were excluded.
© 2019 BJS Society Ltd www.bjs.co.uk BJS 2019; 106: 1341–1351
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Table 1 Clinical and pathological characteristics of patients who
had surgery
No. of patients* (n=181)
Clinical characteristics
Age (years)† 60⋅9(9⋅4)
Sex ratio (F : M) 46 : 135
Bodyweight (kg)† 77⋅7(16⋅4)
BMI (kg/m2)† 27⋅0(4⋅8)
Visceral obesity 55 of 127 (43⋅3)
Sarcopenia 29 of 127 (22⋅8)
Smoker
Ever smoker 125 (69⋅1)
Current smoker 56 (31⋅0)
Pack-years† 21⋅7(28⋅5)
Diabetes 13 (7⋅2)
Ischaemic heart disease 19 (10⋅5)
Hypertension 70 (38⋅7)


































Pulmonary function testing was undertaken routinely
for all patients being considered for surgery. All eligible
Table 1 Continued
No. of patients* (n=181)
Tumour regression grade
TRG 1 40 (22⋅1)
TRG 2 46 (25⋅4)
TRG 3 52 (28⋅7)
TRG 4 30 (16⋅6)
TRG 5 7 (3⋅9)
Not applicable 6 (3⋅3)
pCR 33 (18⋅2)
R0 resection 171 (94⋅5)
*With percentages in parentheses unless indicated otherwise; †values are
mean(s.d.). COPD, chronic obstructive pulmonary disease; pCR, patho-
logical complete response.
patients for whom pulmonary function data were available
at a minimum of one preoperative time point were
included in the analysis of operative and/or oncologi-
cal outcomes. Health-related quality of life (HR-QoL)
among disease-free patients was assessed using validated
questionnaires (European Organisation for Research and
Treatment of Cancer (EORTC) QLQ-C30, QLQ-OG25
and QLQ-OES18)9,10.
The study was approved by the institutional review board
and registered at ClinicalTrials.gov (NCT03462524).
Neoadjuvant therapy and surgery
During the trial, patients with locally advanced
oesophageal cancer received nCRT, either cisplatin and
5-fluorouracil (5-FU) with 40 Gy in 15 fractions or carbo-
platin and paclitaxel with 41⋅4 Gy in 23 fractions)3,11, or
perioperative chemotherapy (etoposide, cisplatin, fluoro-
uracil or capecitabine)12. A lung DVH of V20 (total lung
volume receiving less than 20 Gy of radiation) below 25
per cent was set, with total radiation between 40 and
41⋅4 Gy, and delivery by 3D conformal methods. Patients
underwent resection approximately 6 weeks after com-
pletion of nCRT. The operative approach entailed open
oesophagectomy with a gastric conduit and thoracic or
cervical anastomosis, or extended total gastrectomy with
mediastinal Roux-en-Y reconstruction13,14; transhiatal
resection was used selectively in higher-risk patients13.
Single-lung ventilation was achieved using a
double-lumen endotracheal tube. A multidisciplinary
enhanced recovery protocol was used, with intraoperative
fluid restricted to 500 ml/h, thoracic epidural, immedi-
ate extubation and mobilization on day 1 as standard
in this interval, with all patients post oesophagectomy
monitored in a critical care setting for at least the first
© 2019 BJS Society Ltd www.bjs.co.uk BJS 2019; 106: 1341–1351
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Table 2 Treatment characteristics and postoperative
complications
No. of patients* (n=181)
Chemoradiation regimen
Cisplatin, 5-fluorouracil, 40 Gy/15 fractions 79 (43⋅6)
Carboplatin, paclitaxel, 41⋅4 Gy/23 fractions 101 (55⋅8)
Missing 1 (0⋅6)
Operation type
Extended total gastrectomy 6 (3⋅3)
2-stage oesophagectomy 109 (60⋅2)
3-stage oesophagectomy 50 (27⋅6)
Transhiatal oesophagectomy 16 (8⋅8)
Comprehensive complications index score† 20⋅2(19⋅2)
Clavien–Dindo grade
No complication 51 (28⋅2)
Grade I 24 (13⋅3)
Grade II 51 (28⋅2)
Grade IIIa 27 (14⋅9)
Grade IIIb 5 (2⋅8)
Grade IVa 9 (5⋅0)
Grade IVb 12 (6⋅6)
≥ IIIb 28 (15⋅5)
Anastomotic leak 10 (5⋅5)
Pulmonary complication 80 (44⋅2)
Major pulmonary complication 26 (14⋅4)
Pneumonia 56 (30⋅9)
Prolonged intubation 24 (13⋅3)
Atrial fibrillation 36 (19⋅9)
Major cardiac morbidity 3 (1⋅7)
Critical care LOS (days)‡ 4 (0–85)
Inpatient LOS (days)‡ 16 (6–201)
In-hospital death 2 (1⋅1)
*With percentages in parentheses unless indicated otherwise; values are
†mean(s.d.) and ‡median (range). Major postoperative pulmonary compli-
cation defined as grade IIIb or greater. LOS, length of stay.
48 h after surgery. All patients were seen by respiratory
physiotherapists on the day after operation and underwent
personalized intensive respiratory physiotherapy until dis-
charge. A 10-Fr needle catheter jejunostomy was routinely
placed at surgery, and feeding commenced on the first
postoperative day15. All patients underwent nutritional
and physiotherapy assessment at a multidisciplinary clinic
at diagnosis, before surgery and at serial postoperative
time points, as described previously16,17.
Postoperative complications were coded using the
Clavien–Dindo classification18 and comprehensive
complications index (CCI)19. Postoperative pulmonary
complications were defined according to the criteria
of the Esophageal Complications Consensus Group20,
and pneumonia was diagnosed clinically in accordance
with guidelines of the Centers for Disease Control and
Prevention21. Prolonged intubation was defined as respi-
ratory failure of any aetiology requiring reintubation or
mechanical ventilation more than 24 h after operation.
Pulmonary function testing
Pulmonary physiology, including diffusion capacity for car-
bon monoxide (DLCO), forced expiratory volume in 1 s
(FEV1) and forced vital capacity (FVC), was assessed in the
pulmonary laboratory at baseline and 1 month after com-
pletion of neoadjuvant therapy using the Vmax® Encore
PFT system (Vyaire Medical, Mettawa, Illinois, USA), in
accordance with European Respiratory Society (ERS) and
American Thoracic Society technical standards22. DLCO
values are expressed uncorrected, in SI units (mmol per
min per kPa), in accordance with ERS guidelines22. Ref-
erence values normalized for age, sex, height and ethnic-
ity were generated using Global Lung Function Initiative
equations; pulmonary function measures are expressed as
the percentage of predicted values23,24. Radiation-induced
lung injury was defined according to EORTC common
toxicity criteria, and the incidence of lung injury of grade 2
or above was monitored.
Statistical analysis
Continuous data are reported as mean(s.d.) unless specified
otherwise. Univariable comparisons were performed using
linear regression, Student’s t test or the Mann–Whitney U
test for continuous variables, and the χ2 or Fisher’s exact
test for categorical variables. For multivariable analyses,
clinically relevant variables were included in linear, logistic
or Cox proportional hazards regression models using a for-
ward stepwise selection procedure. The predictive accuracy
of baseline pulmonary function with respect to subsequent
radiation-induced lung injury was assessed using receiver
operating characteristic (ROC) curve analysis. P < 0⋅050
was considered statistically significant. Data were ana-
lysed using GraphPad Prism® version 6.0 for Windows®
(GraphPad Software, San Diego, California, USA) and
SPSS® version 23.0 (IBM, Armonk, New York, USA).
Results
A total of 228 patients received nCRT and these represent
the study cohort (Fig. 1). One hundred and thirty-three
patients (58⋅3 per cent) received carboplatin and pacli-
taxel with 41⋅4 Gy, whereas 93 (40⋅8 per cent) received
cisplatin and 5-FU with 40 Gy; the regimen was not avail-
able for two patients who had nCRT at another hospi-
tal. Some 181 patients underwent resection with curative
© 2019 BJS Society Ltd www.bjs.co.uk BJS 2019; 106: 1341–1351
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Fig. 2 Changes in pulmonary function after neoadjuvant chemoradiation
Baseline
a  FEV1 b  FVC








































































a Forced expiratory volume in 1 s (FEV1), b forced vital capacity (FVC), c FEV1/FVC ratio and d diffusion capacity for carbon monoxide (DLCO).
*P = 0⋅015, †P = 0⋅001, ‡P < 0⋅001 (paired Student’s t test). Individual values and mean(s.d.) values are shown.
intent following completion of neoadjuvant therapy. Clini-
copathological and treatment characteristics of the patients
who had surgery are outlined in Tables 1 and 2.
Change in pulmonary function following
neoadjuvant therapy
A statistically significant decline in FEV1 from 96⋅8(17⋅7)
to 91⋅5(20⋅4) per cent (–3⋅6(10⋅6) per cent; P < 0⋅001),
FVC from 104⋅9(15⋅6) to 98⋅1(19⋅8) per cent (–3⋅2(11⋅9)
per cent; P = 0⋅005) and DLCO from 97⋅6(20⋅7) to
82⋅2(20⋅4) per cent (–14⋅8(14⋅0) per cent; P < 0⋅001)
was observed after nCRT (Fig. 2 and Table 3). The
post-treatment change in percentage predicted DLCO
was unrelated to percentage changes in haemoglobin
(R2 = 0⋅03, P = 0⋅344). No change in the FEV1/FVC ratio
was noted (P = 0⋅552).
Reduced post-treatment DLCO was independently
associated with smoking (P = 0⋅005) and increased age
(P< 0⋅001), whereas smoking was independently associ-
ated with a greater absolute and relative decline in DLCO
(Table S1, supporting information). Patients treated with
carboplatin and paclitaxel with 41⋅4 Gy had greater base-
line DLCO values than those receiving cisplatin and
5-FU with 40 Gy (101⋅3(18⋅3) versus 88⋅3(23⋅6) per cent;
P = 0⋅003). However, the decline in DLCO was greater
in this group (–16⋅2(12⋅2) versus –5⋅1(16⋅8) per cent;
P = 0⋅001); this persisted after accounting for baseline
DLCO and smoking on multivariable analysis (β (s.e.) 95
per cent c.i. –9⋅67 (2⋅89) to 15⋅42 (3⋅92); P = 0⋅001). Post-
© 2019 BJS Society Ltd www.bjs.co.uk BJS 2019; 106: 1341–1351
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Table 3 Pulmonary function measured at baseline and after




FEV1 (% predicted) 96⋅8(17⋅7)
FVC (litres) 4⋅09(0⋅98)
FVC (% predicted) 104⋅9(15⋅6)
FEV1/FVC (%) 71⋅7(9⋅6)
DLCO (mmol per min per kPa) 7⋅83(2⋅20)
DLCO (% predicted) 97⋅6(20⋅7)
Preoperative
FEV1 (litres) 2⋅81(0⋅81)
FEV1 (% predicted) 91⋅5(20⋅4)
FVC (litres) 3⋅87(1⋅03)
FVC (% predicted) 98⋅1(19⋅8)
FEV1/FVC (%) 72⋅6(9⋅3)
DLCO (mmol per min per kPa) 6⋅62(1⋅81)
DLCO (% predicted) 82⋅2(20⋅4)







Values are mean(s.d.). FEV1, forced expiratory volume in 1 s; FVC, forced
vital capacity; DFCO, diffusion capacity for carbon monoxide. Δ, change
in.
treatment DLCO values were similar in the two treat-
ment groups (83⋅5(20⋅7) versus 79⋅9(19⋅9) per cent;
P = 0⋅273).
After nCRT, five patients (2⋅2 per cent) developed
radiation-induced lung injury precluding surgical resec-
tion. Patients with lung injury exhibited a greater relative
change in FEV1 (–18⋅6(14⋅1) versus –2⋅1(12⋅9) per
cent; P = 0⋅002), FVC (–21⋅4(16⋅7) versus –2⋅0(10⋅8)
per cent; P = 0⋅002) and DLCO (–29⋅9(10⋅9) versus
–13⋅4(13⋅7) per cent; P = 0⋅019) during treatment, and
significantly reduced post-treatment DLCO (52⋅5(12⋅8)
versus 82⋅9(20⋅0) per cent; P = 0⋅003). Radiation-induced
lung injury was associated with lower baseline DLCO val-
ues (74⋅1(8⋅8) versus 98⋅2(20⋅6) per cent; P = 0⋅021) and a
history of respiratory co-morbidity (3 of 5 (60 per cent) ver-
sus 46 of 223 (20⋅6 per cent); P = 0⋅034). Neither baseline
FEV1 and FVC, nor neoadjuvant chemoradiation regimen,
predicted subsequent radiation-induced lung injury.
On ROC analysis, baseline DLCO demonstrated 85
(s.e. 4) per cent accuracy (P = 0⋅017) for the prediction
of subsequent lung injury precluding surgery (Fig. 3).
A threshold baseline DLCO of less than 81⋅5 per cent
Fig. 3 Receiver operating characteristic curve analysis of


















On receiver operating characteristic (ROC) curve analysis, baseline diffu-
sion capacity for carbon monoxide predicted subsequent radiation-induced
lung injury precluding operation with 85 (s.e. 4) per cent accuracy
(P = 0⋅017).
predicted radiation-induced lung injury with 100 per cent
sensitivity and 79 per cent specificity.
Neoadjuvant therapy, pulmonary function
and operative morbidity
Among the 181 patients who underwent resection, pul-
monary complications, major pulmonary complications
and prolonged intubation for respiratory failure occurred
in 80 (44⋅2 per cent), 26 (14⋅4 per cent) and 24 (13⋅3 per
cent) patients, with an in-hospital mortality rate of 1⋅1 per
cent (2 patients died) (Table 2). Reduced FVC indepen-
dently predicted the risk of pneumonia (odds ratio (OR)
0⋅97, 95 per cent c.i. 0⋅95 to 0⋅99) (Table 4) and postopera-
tive pulmonary complications (OR 0⋅96, 0⋅94 to 0⋅99).
Patients who required prolonged intubation for respi-
ratory failure had significantly lower preoperative DLCO
(75⋅4(17⋅8) versus 85⋅4(19⋅6) per cent; P = 0⋅030), but not
FEV1 (95⋅6(25⋅4) versus 97⋅6(16⋅7) per cent; P = 0⋅666) or
FVC (100⋅0(14⋅8) versus 105⋅6(15⋅4) per cent; P = 0⋅170).
On multivariable analysis, lower post-treatment DLCO
(OR 0⋅97, 0⋅94 to 1⋅00) and increased FEV1/FVC ratio
(OR 1⋅09 1⋅02 to 1⋅16), indicative of a restrictive pattern of
lung disease, independently predicted the risk of prolonged
intubation (Table 4). A threshold DLCO of less than 65⋅0
per cent demonstrated 90 per cent specificity for the pre-
diction of prolonged intubation.
© 2019 BJS Society Ltd www.bjs.co.uk BJS 2019; 106: 1341–1351
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Table 4 Logistic regression analysis for prediction of factors associated with postoperative pulmonary morbidity among patients with
locally advanced oesophageal cancer following neoadjuvant chemoradiation
Pneumonia Prolonged intubation
Univariable analysis Multivariable analysis Univariable analysis Multivariable analysis
Odds ratio P Odds ratio P Odds ratio P Odds ratio P
Clinical characteristics
Age (years)* 1⋅04 (1⋅00, 1⋅08) 0⋅028 1⋅06 (1⋅01, 1⋅11) 0⋅011 1⋅07 (1⋅01, 1⋅13) 0⋅021 1⋅07 (1⋅01, 1⋅14) 0⋅038
Sex (M versus F) 1⋅29 (0⋅62, 2⋅69) 0⋅489 0⋅208 1⋅44 (0⋅51, 4⋅10) 0⋅493 0⋅290
Weight (kg)* 1⋅00 (0⋅98, 1⋅02) 0⋅788 0⋅888 1⋅00 (0⋅98, 1⋅03) 0⋅747 0⋅811
ASA grade† 0⋅824 0⋅856 0⋅381 0⋅824
Smoking† 0⋅896 0⋅783 0⋅600 0⋅914
Diabetes 0⋅67 (0⋅18, 2⋅53) 0⋅552 0⋅234 0⋅54 (0⋅07, 4⋅32) 0⋅558 0⋅188
Ischaemic heart disease 1⋅38 (0⋅51, 3⋅72) 0⋅523 0⋅584 1⋅93 (0⋅58, 6⋅41) 0⋅281 0⋅814
Respiratory co-morbidity 1⋅12 (0⋅50, 2⋅48) 0⋅788 0⋅713 0⋅87 (0⋅28, 2⋅72) 0⋅806 0⋅856
Asthma 0⋅98 (0⋅24, 3⋅93) 0⋅975 0⋅745 0⋅73 (0⋅09, 6⋅03) 0⋅770 0⋅808
COPD 1⋅30 (0⋅41, 4⋅06) 0⋅656 0⋅689 1⋅12 (0⋅24, 5⋅35) 0⋅886 0⋅853
Histological type 1⋅55 (0⋅77, 3⋅10) 0⋅218 0⋅287 1⋅20 (0⋅46, 3⋅09) 0⋅713 0⋅825
Chemoradiation regimen (CROSS
regimen versus cisplatin/5-FU/40 Gy)
1⋅17 (0⋅62, 2⋅21) 0⋅632 0⋅738 1⋅66 (0⋅67, 4⋅09) 0⋅275 0⋅238
Operative approach (transthoracic
versus transhiatal)
0⋅81 (0⋅31, 2⋅16) 0⋅677 0⋅925 0⋅85 (0⋅23, 3⋅15) 0⋅808 0⋅627
Preoperative pulmonary function*
FEV1 (litres) 0⋅64 (0⋅41, 1⋅01) 0⋅057 0⋅273 0⋅85 (0⋅47, 1⋅56) 0⋅601 0⋅633
FEV1 (% predicted) 0⋅98 (0⋅97, 1⋅00) 0⋅069 0⋅087 0⋅99 (0⋅97, 1⋅02) 0⋅664 0⋅845
FVC (per litre) 0⋅63 (0⋅43, 0⋅92) 0⋅016 0⋅898 0⋅72 (0⋅43, 1⋅19) 0⋅199 0⋅726
FVC (% predicted) 0⋅97 (0⋅95, 0⋅99) 0⋅005 0⋅97 (0⋅95, 0⋅99) 0⋅004 0⋅98 (0⋅96, 1⋅00) 0⋅094 0⋅938
FEV1/FVC (%) 1⋅02 (0⋅98, 1⋅06) 0⋅297 0⋅054 1⋅05 (0⋅99, 1⋅11) 0⋅137 1⋅09 (1⋅02, 1⋅16) 0⋅011
DLCO (mmol per min per kPa) 0⋅84 (0⋅69, 1⋅04) 0⋅111 0⋅525 0⋅74 (0⋅54, 1⋅00) 0⋅051 0⋅916
DLCO (% predicted) 0⋅99 (0⋅97, 1⋅00) 0⋅113 0⋅425 0⋅98 (0⋅95, 1⋅00) 0⋅038 0⋅97 (0⋅94, 1⋅00) 0⋅020
Values in parentheses are 95 per cent confidence intervals. COPD, chronic obstructive pulmonary disease; 5-FU, 5-fluorouracil; FEV1, forced expiratory
volume in 1 s; FVC, forced vital capacity; DFCO, diffusion capacity for carbon monoxide. *Odds ratios for continuous variables are shown per unit increase.
†Analysed as a categorical variable; individual category P values and odds ratios not significant.
Reduced post-treatment DLCO was associated with
increased CCI on univariable analysis (P = 0⋅010), whereas
lower post-treatment DLCO (P = 0⋅006) and increased
FEV1/FVC ratio (P = 0⋅009) independently predicted
CCI on multivariable analysis (Table S2, supporting
information).
Pulmonary function and health-related quality
of life
Among those who were disease-free 1 year or more
after surgery (104 patients, with HR-QoL data avail-
able for 40), reduced post-nCRT DLCO was associated
with poorer physical function (P = 0⋅047) and subjec-
tive trouble taking a long outdoor walk (P = 0⋅011). The
neoadjuvant regimen did not influence physical func-
tion or HR-QoL in survivorship. Similarly, no baseline
or post-treatment pulmonary function parameter had a
significant impact on overall HR-QoL. On multivariable
analysis, background respiratory co-morbidity (P = 0⋅011)
and lower post-treatment DLCO (P = 0⋅038) indepen-
dently predicted poorer physical function scores.
Discussion
This study has highlighted the fact that pulmonary phys-
iology is altered negatively by modern nCRT protocols,
and the impact, although nuanced and subclinical, can
have a direct influence on risks of postoperative pulmonary
complications and recovery of quality of life. Although
FEV1 and FVC were significantly reduced by nCRT,
the loss of diffusion capacity, measured by DLCO, was
most pronounced and associated with clinical outcomes.
The overall mean decrease in DLCO was 14⋅8 per cent
compared with less than 4 per cent each for FEV1 and
FVC, the latter functional lung volume data being con-
sistent with those of the NeoRes trial25. In NeoRes,
however, DLCO was not measured and, despite detailed
© 2019 BJS Society Ltd www.bjs.co.uk BJS 2019; 106: 1341–1351
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cardiopulmonary evaluation, the increased burden of
major pulmonary morbidity among patients treated with
nCRT remained unexplained.
On the other hand, in a study of 20 patients receiving
50⋅4 Gy, oxaliplatin and 5-FU, Gergel and colleagues26
reported a 16⋅9 per cent reduction in DLCO, with a
decrease of 2⋅5 per cent in total lung capacity. Similarly, in
a study from the Cleveland Clinic27, including 155 patients
treated with a combination regimen including cisplatin
and 5-FU, 108 of whom received 45 Gy and 47 received
30 Gy, decreases in DLCO of 21⋅7 and 8⋅6 per cent respec-
tively were observed27. This dose–response effect is con-
sistent with the results of Riedel et al.28, who reported no
significant change in pulmonary function in 77 patients
with locally advanced oesophageal cancer, with grade 1
radiation-induced lung injury in just one patient (1 per
cent) after treatment with 5-FU and 30 Gy.
In the present study, although radiation doses were
similar and the chemotherapy regimens varied, a greater
decline in DLCO was observed following administra-
tion of the CROSS regimen (carboplatin, paclitaxel
and 41⋅4 Gy) compared with cisplatin, 5-FU and 40 Gy.
Although baseline differences in pulmonary function,
and the non-contemporaneous nature of the cohorts,
preclude definitive conclusions being drawn from these
data, administration of carboplatin and paclitaxel with
neoadjuvant radiation has been reported to increase syner-
gistically the risk of radiation-induced lung injury, with a
3⋅3-fold increased risk of at least grade 2 lung injury among
patients with non-small cell lung carcinoma, and increased
pneumonitis in those with oesophageal cancer29,30. Fur-
thermore, in a contemporaneous cohort of 156 patients
undergoing neoadjuvant chemotherapy at the authors’
centre, although reductions in DLCO were observed
(P < 0⋅001), the relative reduction in DLCO was signifi-
cantly greater after chemoradiation (–14⋅8(14⋅0) per cent
for nCRT in the present cohort versus –7⋅3(14⋅9) per cent
for neoadjuvant chemotherapy in the contemporaneous
cohort; P = 0⋅003), and on multivariable analysis chemora-
diation independently predicted the absolute (P = 0⋅017)
and relative (P = 0⋅018) decline in DLCO during neoad-
juvant treatment (data not shown). Importantly, in the
present study, reduced baseline DLCO was associated with
an increased risk of lung injury precluding surgery, with a
threshold of less than 81⋅5 per cent exhibiting 79 per cent
specificity for prediction of such injury.
Although clinically evident lung injury is rare, observed
in just five patients here (2⋅2 per cent), this study
has identified important associations between reduced
diffusion capacity and clinical consequences, in particular
respiratory failure, prolonged intubation, increased
CCI and major pulmonary morbidity. Specifically, a
post-treatment DLCO of less than 65⋅0 per cent predicted
postoperative respiratory failure and prolonged intu-
bation with 90 per cent specificity. The mechanisms
linking changes in pulmonary physiology to postoperative
complications require further investigation. Whether
radiation-induced lung injury occurs as a consequence of
direct radiation injury, perhaps in synergy with taxane-
induced pneumonitis, or a ‘first hit’ sensitization or priming
of alveolar and immune cells to an exaggerated immune and
inflammatory response to a ‘second hit’ such as single-lung
ventilation, bacteraemia or pneumonia, is uncertain31.
Fibrosis is thought to occur owing to activation of latent
transforming growth factor (TGF) β, which increases
the generation of reactive oxygen species via reduced
nicotinamide adenine dinucleotide phosphate oxidases and
resulting activation of SMAD, stimulating myofibroblast
proliferation via epithelial-to-mesenchymal transition,
and promoting extracellular matrix deposition31. These
changes perpetuate tissue hypoxia and manifest as impaired
diffusion, with overt fibrosis and hypoxemia its most severe
clinical expression. Experimentally, increased circulating
levels of TGF-β1, as well as interleukin (IL) 1α, IL-6 and
monocyte chemoattractant protein 1, have been demon-
strated during the development of radiation-induced lung
injury, suggesting the possibility of biomarker develop-
ment to facilitate treatment modification when features of
lung injury are detected32.
In the present cohort, no difference in postoperative
pulmonary morbidity was observed among patients under-
going transhiatal compared with transthoracic resection,
which is probably a reflection of selective use of this opera-
tive strategy for high-risk patients; the baseline pulmonary
co-morbidity rate was 45⋅0 per cent for patients having
a transhiatal procedure compared with 15⋅5 per cent for
those undergoing a transthoracic procedure (P = 0⋅004). A
transhiatal approach has been suggested for patients with
significant pulmonary co-morbidity, owing to a reduced
incidence of postoperative pulmonary complications and
because the need for single-lung ventilation in obviated33,
and the present data may inform such discussions. How-
ever, minimally invasive approaches may produce similar
benefits for patients with significant baseline pulmonary
co-morbidity34, while producing favourable oncologi-
cal outcomes even compared with open transthoracic
resection35,36.
Longer-term implications of reduced DLCO after
nCRT were also observed, including reduced physical
function scores and increased difficulty in taking a long
outdoor walk among disease-free patients on HR-QoL
analysis, consistent with long-term outcomes in the
© 2019 BJS Society Ltd www.bjs.co.uk BJS 2019; 106: 1341–1351
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NeoRes trial25. Given the short- and long-term implica-
tions of reduced diffusion capacity, there is great impetus
to develop an understanding of the factors, both patient-
and treatment-related, influencing individual risk. Clearly
dose is important, with increased risk at greater total radia-
tion doses, and increased irradiated lung volumes on DVH
analysis26,37,38. Although a DVH of V20 below 25 per cent
was set in the present study, as in the CROSS protocol,
clinical tumour stage tended to predict reduced percentage
DLCO after treatment on multivariable analysis, probably
reflecting planned clinical target volumes with greater
lung exposure. Smoking also independently increased
DLCO loss, an effect also reported in lung cancer, further
emphasizing the need for smoking cessation in patients
commencing multimodal protocols39.
The strength of the study is the detailed profiling of
a large number of patients initially deemed fit for major
surgery based on clinical assessment, with standard oper-
ative approaches underpinned by quality assurance mea-
sures. However, some limitations are acknowledged. First,
although a DVH of V20 below 25 per cent was set for all
patients, individual DVH re-analysis was beyond the scope
of this study. Second, even though multivariable analysis
was undertaken to minimize confounding between groups,
the treatment allocation was not randomized, and so dif-
ferences between the two chemoradiation protocols may
be subject to uncontrolled bias. In addition, these data rep-
resent a single-centre experience; further multicentre col-
laborative efforts may lend external validity to the present
data. Attrition during neoadjuvant therapy was significant
compared with that in clinical trials3,40, but similar to that
of previous consecutive cohort data41,42. Although three
RCTs35,43–45 have reported reduced pulmonary morbid-
ity with minimally invasive approaches, all patients in the
present study underwent open surgery, so the implications
for minimally invasive oesophagectomy are unclear. How-
ever, the present data provide a useful framework for fur-
ther research in this context.
This study has demonstrated that nCRT, although rarely
causing clinically evident radiation fibrosis, is associated
with a significant decline in pulmonary diffusion capacity
overall. Reduced pulmonary diffusion was associated with
an increased risk of major postoperative complications and
impaired long-term quality of life. Prospective detailed
recording of operative morbidity and quality of life is
embedded in ongoing RCTs including ESOPEC and
NeoAEGIS (NEOadjuvant trial in Adenocarcinoma of the
oEsophagus and oesophagoGastric junction International
Study), which are comparing best current chemotherapy
with the CROSS regimen, and these secondary endpoints
will be of major interest, particularly if there is oncological
equivalence46,47. At this time, notwithstanding advances in
minimally invasive approaches, pulmonary complications
remain the most common cause of postoperative major
morbidity and mortality in oesophageal cancer surgery,
and these data provide a rationale towards personalized
treatment where pulmonary physiology, in particular dif-
fusion capacity, a potentially targetable parameter, must be
considered.
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